Insmed, Inc. $INSM Shares Sold by Bayforest Capital Ltd

Key Points

• Bayforest Capital Ltd reduced its stake in Insmed, Inc. by 41.9% in the second quarter, resulting in ownership of 4,098 shares worth $412,000.
• Insmed's recent earnings report showed a loss of ($1.70) per share, missing analysts' expectations, despite a 18.9% increase in quarterly revenue year-over-year.
• Analysts have raised their price targets for Insmed, with most giving the stock a consensus rating of "Moderate Buy" and a target price of approximately $152.88.

Bayforest Capital Ltd decreased its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 41.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,098 shares of the biopharmaceutical company's stock after selling 2,956 shares during the quarter. Bayforest Capital Ltd's holdings in Insmed were worth $412,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its position in Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company's stock worth $262,967,000 after acquiring an additional 1,799,382 shares during the period. Nuveen LLC purchased a new position in shares of Insmed in the first quarter worth about $88,351,000. Duquesne Family Office LLC raised its stake in shares of Insmed by 130.7% in the first quarter. Duquesne Family Office LLC now owns 1,369,050 shares of the biopharmaceutical company's stock worth $104,445,000 after purchasing an additional 775,580 shares during the last quarter. 1832 Asset Management L.P. purchased a new position in shares of Insmed in the first quarter worth about $37,214,000. Finally, Wellington Management Group LLP raised its stake in shares of Insmed by 62.5% in the first quarter. Wellington Management Group LLP now owns 1,222,627 shares of the biopharmaceutical company's stock worth $93,274,000 after purchasing an additional 470,401 shares during the last quarter.

Insmed Stock Up 1.3%

INSM opened at $163.54 on Thursday. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $166.44. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company has a fifty day moving average of $141.18 and a two-hundred day moving average of $103.59. The stock has a market capitalization of $34.57 billion, a price-to-earnings ratio of -28.64 and a beta of 1.03.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. During the same period in the previous year, the firm posted ($1.94) EPS. The firm's quarterly revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

INSM has been the subject of several research reports. Mizuho lifted their price objective on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. The Goldman Sachs Group raised their target price on shares of Insmed from $121.00 to $196.00 and gave the stock a "buy" rating in a report on Friday, October 3rd. Royal Bank Of Canada raised their target price on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. UBS Group raised their target price on shares of Insmed from $140.00 to $194.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, TD Cowen lifted their price objective on Insmed from $154.00 to $193.00 and gave the company a "buy" rating in a research note on Thursday, October 2nd. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $152.88.

Insider Transactions at Insmed

In other news, insider Michael Alexander Smith sold 24,272 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the sale, the insider directly owned 54,902 shares in the company, valued at $7,899,848.78. The trade was a 30.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Sara Bonstein sold 58,400 shares of the company's stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the transaction, the chief financial officer owned 73,505 shares of the company's stock, valued at $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 211,057 shares of company stock worth $27,438,126 over the last quarter. Company insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.